明显的尿酸轨迹与发生的心脏导电阻有关
Na Li1,2, Liufu Cui2, Rong Shu2
1Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, No. 23, Pingjiang Road, Hexi District, Tianjin, 300211, People's Republic of China.
Arthritis research & therapy
|February 27, 2024
概括
随着时间的推移,稳定的中等和高尿酸水平 (UA) 会增加患心脏导电阻塞的风险. 监测UA轨迹可以帮助识别患有这种心脏病的风险人群.
科学领域:
- 心脏病学 心脏病学
- 代谢健康 代谢健康
- 流行病学 流行病学
背景情况:
- 长期尿酸水平变化与心脏导电阻塞风险之间的关系尚不清楚.
- 了解这些关联对于预测和预防心血管事件至关重要.
研究的目的:
- 为了确定尿酸 (UA) 水平的独特纵向轨迹.
- 调查这些UA轨迹与患心脏导电阻塞的风险之间的关联.
主要方法:
- 利用了凯卢安队列 (2006-2012) 中67,095名参与者的数据.
- 采用基于组的轨迹建模来定义UA模式.
- 应用了Cox比例危险回归来分析UA轨迹与心脏导电阻塞发生率之间的联系.
主要成果:
- 确定了三个UA轨迹:低稳定,中等稳定和高稳定.
- 中等稳定和高稳定UA轨迹与心脏导电阻塞风险增加显著相关 (HRs分别为1.30和1.86).
- 即使在正常范围内的中度稳定UA水平中也观察到高风险,这表明尽管表面上是正常水平,但存在潜在风险.
结论:
- 中等稳定和高稳定尿酸 (UA) 轨迹都与新发性心脏导电阻塞的更高风险有关.
- 随着时间的推移,监测UA水平的变化可能有助于识别易受心脏导电阻塞的个体.
相关概念视频
Disturbances in Heart Rhythm
952
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
952
Mechanism of Cardiac Arrhythmias
919
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
919
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
512
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
512
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
994
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
994


